Schulz A, Hasselblatt A
Institut für Pharmakologie und Toxikologie, Universität Göttingen, Federal Republic of Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1988 Jun;337(6):637-43. doi: 10.1007/BF00175789.
We investigated the effects of phentolamine and another more selective alpha 2-adrenoceptor antagonist, rauwolscine, on insulin release in vivo (in female Wistar-rats) and in vitro (in perfused rat pancreas and in isolated perifused mouse islets). Phentolamine was found to significantly increase glucose-induced insulin release. On the other hand, rauwolscine failed to do so, when applied in a concentration that effectively antagonized the inhibitory effect of clonidine. These results demonstrate that phentolamine is capable of directly stimulating insulin release. This effect is thus not mediated by alpha-adrenoceptors. For this reason phentolamine is not an appropriate tool to study possible inhibitory effects of the sympathetic nervous system on insulin release. An enhanced insulin response as may be observed in animals and in man in the presence of phentolamine does not furnish evidence for a tonic inhibitory control of the islet cells by the sympathetic nervous system.
我们研究了酚妥拉明和另一种更具选择性的α2-肾上腺素能受体拮抗剂萝芙辛对体内(雌性Wistar大鼠)和体外(灌注大鼠胰腺和分离的灌注小鼠胰岛)胰岛素释放的影响。发现酚妥拉明能显著增加葡萄糖诱导的胰岛素释放。另一方面,当以有效拮抗可乐定抑制作用的浓度应用时,萝芙辛未能如此。这些结果表明酚妥拉明能够直接刺激胰岛素释放。因此这种作用不是由α-肾上腺素能受体介导的。出于这个原因,酚妥拉明不是研究交感神经系统对胰岛素释放可能的抑制作用的合适工具。在酚妥拉明存在的情况下,动物和人类中可能观察到的增强的胰岛素反应并不能为交感神经系统对胰岛细胞的紧张性抑制控制提供证据。